To compare the safety and efficacy of BLI-801 administered at 4 dose levels in constipated adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Unnamed facility
Anaheim, California, United States
Unnamed facility
Cranston, Rhode Island, United States
Unnamed facility
Cumberland, Rhode Island, United States
Bowel Movement Count
Time frame: 24 hours
Adverse events
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dose 4